{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:34:17Z","timestamp":1791182057933,"version":"4.1.0"},"reference-count":95,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Indolent systemic mastocytosis (SM) patients have a varied clinical presentation, ranging from predominantly cutaneous symptoms to recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threatening (anaphylaxis). Mastocytosis patients without skin involvement pose a diagnostic challenge; a high index of suspicion is needed in those with mast cell\u2013degranulation symptoms, including anaphylaxis following Hymenoptera stings or other triggers. Modern-era molecular and flow-cytometric diagnostic methods are very sensitive and can detect minimal involvement of bone marrow with atypical\/clonal mast cells; in some cases, full diagnostic criteria for SM are not fulfilled. An important aspect of treatment is avoidance of known symptom triggers; other treatment principles include a stepwise escalation of antimediator therapies and consideration of cytoreductive therapies for those with treatment-refractory symptoms. The perioperative management of mastocytosis patients is nontrivial; a multidisciplinary preoperative assessment, adequate premedications, and close intra- and postoperative monitoring are critical. Smoldering mastocytosis is a variant with high systemic mast cell burden. While its clinical course can be variable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribine) in this setting. A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here.<\/jats:p>","DOI":"10.1182\/blood-2013-01-453183","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T07:21:51Z","timestamp":1361431311000},"page":"3085-3094","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)"],"prefix":"10.1182","volume":"121","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817090548700_B1","author":"Horny"},{"issue":"23","key":"2019111817090548700_B2","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"26","key":"2019111817090548700_B3","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis.","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111817090548700_B4","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111817090548700_B5","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111817090548700_B6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"2019111817090548700_B7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0145-2126(01)00157-6","article-title":"Classification of cutaneous mastocytosis: a modified consensus proposal.","volume":"26","author":"Hartmann","year":"2002","journal-title":"Leuk Res"},{"issue":"4","key":"2019111817090548700_B8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1365-2133.2001.04123.x","article-title":"Mastocytosis: recent advances in defining the disease.","volume":"144","author":"Hartmann","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"2019111817090548700_B9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2019111817090548700_B10","author":"Lanternier"},{"issue":"5","key":"2019111817090548700_B11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111817090548700_B12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archderm.1963.01590140008002","article-title":"The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases.","volume":"87","author":"Caplan","year":"1963","journal-title":"Arch Dermatol"},{"issue":"4","key":"2019111817090548700_B13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archderm.1986.01660160078023","article-title":"The bone marrow in urticaria pigmentosa and systemic mastocytosis. Cell composition and mast cell density in relation to urinary excretion of tele-methylimidazoleacetic acid.","volume":"122","author":"Ridell","year":"1986","journal-title":"Arch Dermatol"},{"issue":"7","key":"2019111817090548700_B14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0145-2126(01)00044-3","article-title":"Clinical and histopathological aspects of cutaneous mastocytosis.","volume":"25","author":"Wolff","year":"2001","journal-title":"Leuk Res"},{"issue":"1 Pt 1","key":"2019111817090548700_B15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(88)70007-9","article-title":"Bone marrow findings in adult patients with urticaria pigmentosa.","volume":"18","author":"Czarnetzki","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2019111817090548700_B16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis.","volume":"24","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"2019111817090548700_B17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults.","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111817090548700_B18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"2019111817090548700_B19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.","volume":"67","author":"van Doormaal","year":"2012","journal-title":"Allergy"},{"issue":"3","key":"2019111817090548700_B20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"2019111817090548700_B21","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.","volume":"96","author":"Schwartz","year":"1995","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111817090548700_B22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders.","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"issue":"4","key":"2019111817090548700_B23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2011.192","article-title":"Immunophenotyping in systemic mastocytosis diagnosis: \u2018CD25 positive\u2019 alone is more informative than the \u2018CD25 and\/or CD2\u2019 WHO criterion.","volume":"25","author":"Morgado","year":"2012","journal-title":"Mod Pathol"},{"issue":"5","key":"2019111817090548700_B24","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis.","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS ONE"},{"issue":"7","key":"2019111817090548700_B25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clineuro.2011.05.002","article-title":"Neurologic symptoms and diagnosis in adults with mast cell disease.","volume":"113","author":"Smith","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"2019111817090548700_B26","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"2019111817090548700_B27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00015550152572912","article-title":"Clinical scoring of cutaneous mastocytosis.","volume":"81","author":"Heide","year":"2001","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"2019111817090548700_B28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2230.2008.03005.x","article-title":"Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis.","volume":"34","author":"Heide","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2019111817090548700_B29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology.","volume":"48","author":"Brockow","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2019111817090548700_B30","first-page":"345","article-title":"Interferon alpha and systemic mastocytosis. Analysis of therapeutic efficacy in 6 cases.","volume":"198","author":"Giraldo Castellano","year":"1998","journal-title":"Rev Clin Esp"},{"issue":"4","key":"2019111817090548700_B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000329218","article-title":"Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.","volume":"157","author":"Wimazal","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"2019111817090548700_B32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis.","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2019111817090548700_B33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111817090548700_B34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"issue":"3-4","key":"2019111817090548700_B35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis.","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"2","key":"2019111817090548700_B36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"2019111817090548700_B37","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"8","key":"2019111817090548700_B38","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111817090548700_B39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"issue":"5","key":"2019111817090548700_B40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111817090548700_B41","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111817090548700_B42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111817090548700_B43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11882-009-0010-9","article-title":"The problem of anaphylaxis and mastocytosis.","volume":"9","author":"M\u00fcller","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"issue":"10","key":"2019111817090548700_B44","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA).","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"2019111817090548700_B45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"2019111817090548700_B46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000083954","article-title":"Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.","volume":"136","author":"Florian","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"2019111817090548700_B47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/ACI.0b013e3282a6443e","article-title":"Mastocytosis and allergy.","volume":"7","author":"Greenhawt","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"2019111817090548700_B48","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis.","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111817090548700_B49","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2019111817090548700_B50","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"issue":"7","key":"2019111817090548700_B51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"issue":"1","key":"2019111817090548700_B52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/000313480907500115","article-title":"Guidelines for safe surgery in patients with systemic mastocytosis.","volume":"75","author":"Chaar","year":"2009","journal-title":"Am Surg"},{"issue":"2","key":"2019111817090548700_B53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1399-6576.2008.01780.x","article-title":"Anaesthesia in patients with mastocytosis.","volume":"53","author":"Konrad","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"issue":"5","key":"2019111817090548700_B54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization.","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2019111817090548700_B55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12630-011-9472-z","article-title":"Case Report: perioperative immediate hypersensitivity involves not only allergy but also mastocytosis.","volume":"58","author":"Renauld","year":"2011","journal-title":"Can J Anaesth"},{"issue":"4","key":"2019111817090548700_B56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e328355b7cb","article-title":"Drug allergy in mast cell disease.","volume":"12","author":"Brockow","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"2019111817090548700_B57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1460-9592.2008.02904.x","article-title":"Anesthesia in children with mastocytosis\u2014a case based review.","volume":"19","author":"Ahmad","year":"2009","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"2019111817090548700_B58","first-page":"442","article-title":"Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice.","volume":"21","author":"Mertes","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"2019111817090548700_B59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy.","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"2019111817090548700_B60","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2019111817090548700_B61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaci.2009.02.003","article-title":"Assessing anaphylactic risk? Consider mast cell clonality.","volume":"123","author":"Metcalfe","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2019111817090548700_B62","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1398-9995.2009.02108.x","article-title":"How much specific is the association between hymenoptera venom allergy and mastocytosis?","volume":"64","author":"Bonadonna","year":"2009","journal-title":"Allergy"},{"issue":"9","key":"2019111817090548700_B63","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1046\/j.1365-2222.2003.01755.x","article-title":"Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.","volume":"33","author":"Haeberli","year":"2003","journal-title":"Clin Exp Allergy"},{"issue":"9267","key":"2019111817090548700_B64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(00)04677-8","article-title":"Hymenoptera stings and serum tryptase.","volume":"357","author":"Krishna","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"2019111817090548700_B65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0091-6749(97)70188-X","article-title":"Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.","volume":"100","author":"Fricker","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2019111817090548700_B66","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy.","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"issue":"5","key":"2019111817090548700_B67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/imt.11.44","article-title":"Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.","volume":"3","author":"Gonz\u00e1lez-de-Olano","year":"2011","journal-title":"Immunotherapy"},{"issue":"2","key":"2019111817090548700_B68","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.","volume":"121","author":"Gonz\u00e1lez-de-Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2019111817090548700_B69","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1365-2222.2011.03788.x","article-title":"Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines.","volume":"41","author":"Krishna","year":"2011","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"2019111817090548700_B70","first-page":"ECR26","article-title":"Systemic mastocytosis: bone marrow involvement assessed by Tc-99m MDP scintigraphy and magnetic resonance imaging.","volume":"88","author":"Di Leo","year":"2003","journal-title":"Haematologica"},{"issue":"10","key":"2019111817090548700_B71","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients.","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2019111817090548700_B72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"issue":"4","key":"2019111817090548700_B73","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts.","volume":"174","author":"Biosse-Duplan","year":"2009","journal-title":"Am J Pathol"},{"issue":"1","key":"2019111817090548700_B74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation.","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2019111817090548700_B75","author":"Guillaume"},{"issue":"4","key":"2019111817090548700_B76","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"issue":"11","key":"2019111817090548700_B77","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.5650051104","article-title":"Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes.","volume":"5","author":"Graves","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019111817090548700_B78","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1359\/jbmr.2002.17.4.567","article-title":"Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy.","volume":"17","author":"Brumsen","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111817090548700_B79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption.","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"issue":"3","key":"2019111817090548700_B80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis.","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"1","key":"2019111817090548700_B81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","article-title":"Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b.","volume":"72","author":"Weide","year":"1996","journal-title":"Ann Hematol"},{"issue":"9","key":"2019111817090548700_B82","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/rheumatology\/35.9.898","article-title":"Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B.","volume":"35","author":"Lehmann","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"1","key":"2019111817090548700_B83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"issue":"2","key":"2019111817090548700_B84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis.","volume":"26","author":"Laroche","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"8","key":"2019111817090548700_B85","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"2019111817090548700_B86","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111817090548700_B87","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111817090548700_B88","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2019111817090548700_B89","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"issue":"4","key":"2019111817090548700_B90","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.","volume":"87","author":"Pardanani","year":"2012","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111817090548700_B91","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine.","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111817090548700_B92","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis.","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2019111817090548700_B93","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"2019111817090548700_B94","author":"Hermine"},{"key":"2019111817090548700_B95","author":"Gotlib"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/16\/3085\/1329747\/3085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/16\/3085\/1329747\/3085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:16:07Z","timestamp":1714986967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/16\/3085\/31589\/How-I-treat-patients-with-indolent-and-smoldering"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":95,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,4,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-01-453183","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}